<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03968211</url>
  </required_header>
  <id_info>
    <org_study_id>21453</org_study_id>
    <nct_id>NCT03968211</nct_id>
  </id_info>
  <brief_title>Undetectable IgE as a Sentinel Biomarker for Humoral Immunodeficiency</brief_title>
  <official_title>Undetectable IgE as a Sentinel Biomarker for Humoral Immunodeficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CSL Behring</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jeffrey Modell Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is trying to find out if an undetectable serum immunoglobulin E (IgE) is a
      biomarker, or early sign of, the development of immune deficiency.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      IgE is the antibody thought to be responsible for developing allergies. Undetectable serum
      IgE (an IgE below the lower limit of detection) is found in about 3% of the general
      population. In the past, it has been thought that having an undetectable IgE does not have
      any health impact, other than meaning that you are at low risk for having allergies. However,
      recent studies of patients with undetectable IgE have shown higher rates of infections,
      autoimmune disease and cancer.

      Patients with an immune deficiency called common variable immunodeficiency (CVID) also have
      higher rates of infections, autoimmune disease and cancer. Recently, we have shown that most
      patients with CVID have a low/undetectable serum IgE.

      This study is trying to find out if an undetectable serum IgE is a biomarker, or early sign
      of, the development of CVID or other antibody deficiencies
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vaccination response</measure>
    <time_frame>4-6 weeks</time_frame>
    <description>IgG to Salmonella typhi will be measured, with a normal response calculated as at least a 2-fold increase in IgG titers post-vaccination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Epsilon germline transcript production</measure>
    <time_frame>3 days</time_frame>
    <description>B cells isolated from subjects will be evaluated to determine their ability to produce Epsilon germline transcript in response to stimulation</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Immune Deficiency</condition>
  <arm_group>
    <arm_group_label>Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who meet enrollment criteria will be administered a single intramuscular dose of the Salmonella typhi polysaccharide vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Salmonella typhi polysaccharide vaccine</intervention_name>
    <description>Salmonella typhi polysaccharide vaccine</description>
    <arm_group_label>Vaccine</arm_group_label>
    <other_name>Typhim Vi</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-80

          -  Willingness and ability to comply with scheduled visits and study procedures

          -  Undetectable serum IgE (defined as &gt;2 IU/mL or the lower threshold of detection)

          -  Normal or high serum immunoglobulins (within or above laboratory reference range for
             IgG, IgA, and IgM)

          -  patients previously seen at the University of Virginia Asthma, Allergy, and Immunology
             clinics where undetectable serum IgE was noted

          -  Control subjects must have participated in study IRB#14457 (only applicable for
             healthy controls in epsilon germline transcript portion of the study)

        Exclusion Criteria:

          -  The following vulnerable populations will be excluded: pregnant women, fetuses,
             neonates, children, prisoners, cognitively impaired, educational or economically
             disadvantaged, non-English speaking subjects

          -  Known personal history of immunodeficiency

          -  Known personal history of recurrent infections

          -  Low serum immunoglobulins (below the laboratory reference range for IgG, IgA, or IgM)

          -  Recent or current treatment with systemic immunosuppression within the past 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Larry Borish, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Monica G Lawrence, MD</last_name>
    <phone>434-924-5917</phone>
    <email>ml4nz@virginia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kristin Wavell</last_name>
    <phone>434-924-6874</phone>
    <email>kww7d@virginia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristin Wavell</last_name>
      <phone>434-924-6874</phone>
      <email>kww7d@virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Larry Borish, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Monica G Lawrence, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lawrence MG, Palacios-Kibler TV, Workman LJ, Schuyler AJ, Steinke JW, Payne SC, McGowan EC, Patrie J, Fuleihan RL, Sullivan KE, Lugar PL, Hernandez CL, Beakes DE, Verbsky JW, Platts-Mills TAE, Cunningham-Rundles C, Routes JM, Borish L. Low Serum IgE Is a Sensitive and Specific Marker for Common Variable Immunodeficiency (CVID). J Clin Immunol. 2018 Apr;38(3):225-233. doi: 10.1007/s10875-018-0476-0. Epub 2018 Feb 17.</citation>
    <PMID>29453744</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>May 28, 2019</study_first_submitted>
  <study_first_submitted_qc>May 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2019</study_first_posted>
  <last_update_submitted>February 14, 2020</last_update_submitted>
  <last_update_submitted_qc>February 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Larry Borish, MD</investigator_full_name>
    <investigator_title>Professor of Medicine and Microbiology</investigator_title>
  </responsible_party>
  <keyword>immunodeficiency</keyword>
  <keyword>IgE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified IPD that underlie results in a publication will be made available upon request of another researcher or if required by the publisher</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Starting 6 months after publication</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

